

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Brilliant Violet 785(TM) anti-mouse/human CD44

RRID:AB_2571953

Type: Antibody

Proper Citation

BioLegend Cat# 103059, RRID:AB_2571953

Antibody Information

URL: http://antibodyregistry.org/AB_2571953

Proper Citation: BioLegend Cat# 103059, RRID:AB_2571953

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_2571953

Vendor: BioLegend

Catalog Number: 103059

Alternative Catalog Numbers: 103041

Record Creation Time: 20250820T041303+0000

Record Last Update: 20250820T182153+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Linger ME, et al. (2025) Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice. *iScience*, 28(10), 113479.

Chen KY, et al. (2025) Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodes. *Cell*, 188(4), 1019.

Cole AC, et al. (2025) Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. *Cancer cell*, 43(9), 1697.

Ganapathi Sankaran D, et al. (2025) Gene-regulatory programs that specify age-related differences during thymocyte development. *Cell reports*, 44(7), 115903.

Zeng Q, et al. (2025) Gut microbiota-driven pathogenic Th17 cells mediated autoimmune epididymo-orchitis in a mouse model of colitis. *iScience*, 28(5), 112508.

Alicea Pauneto CDM, et al. (2025) Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. *Immunity*.

Scott MC, et al. (2025) Deep profiling deconstructs features associated with memory CD8+ T cell tissue residence. *Immunity*, 58(1), 162.

Galvez-Cancino F, et al. (2025) Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. *Immunity*, 58(5), 1236.

Li H, et al. (2025) T cell-intrinsic cGAS-CTCF regulation maintains regulatory T cell development and function. *Cell reports*, 44(10), 116302.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. *Cell*, 187(16), 4336.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. *Immunity*, 57(7), 1514.

Hunt EG, et al. (2024) Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment. *Cell metabolism*.

Chibaya L, et al. (2024) Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. *Science translational medicine*, 16(762), eadj9366.

Gbedande K, et al. (2024) Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection. *iScience*, 27(12), 111468.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. *Cancer cell*.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. *Cancer cell*, 42(6), 1032.

Waibl Polania J, et al. (2024) Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. *Immunity*.

Rowe JH, et al. (2023) Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade. *Cancer discovery*, 13(12), 2566.

Torow N, et al. (2023) M cell maturation and cDC activation determine the onset of adaptive immune priming in the neonatal Peyer's patch. *Immunity*, 56(6), 1220.